Hutchmed (China) Limited

Declaration of Voting Results & Voting Rights Announcements • Oct 31, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6918F

Hutchison China Meditech Limited

31 October 2018

Total Voting Rights

London: Wednesday, October 31, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at October 31, 2018, the issued share capital of Chi-Med consisted of 66,618,660 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 66,618,660 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

For illustrative purposes only, the 66,618,660 ordinary shares would be equivalent to 66,618,660 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 133,237,320 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1).  For more information, please visit: www.chi-med.com.

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance & Development	+852 2121 8200
David Dible, Citigate Dewe Rogerson	+44 7967 566 919 (Mobile) [email protected]
Xuan Yang, Solebury Trout	+1 (415) 971 9412 (Mobile) [email protected]
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson	+44 7973 611 888 (Mobile) [email protected]
Americas - Brad Miles, Solebury Trout	+1 (917) 570 7340 (Mobile) [email protected]
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick	+852 9850 5033 (Mobile) [email protected]
Mainland China - Sam Shen, Edelman	+86 1367 179 1029 (Mobile) [email protected]
Nominated Advisor
Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited	+44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TVREANEEDASPFEF